ClinicalTrials.gg
SuspendedNCT03304496NITRAD-SubUpdated Mar 18, 2026

Subcutaneous Nitroglycerin to Facilitate Trans-radial Access.

A Phase 4 interventional study of Nitroglycerin 100 MCG/ML Injectable Solution and Saline Solution in Coronary Artery Disease, sponsored by Instituto Nacional de Cardiologia Ignacio Chavez. Suspended at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Instituto Nacional de Cardiologia Ignacio Chavez · Phase 4, Interventional, and Supportive care

Why this study was suspended
The sample was not completed.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Coronary Artery Disease with a site in Mexico — 8 open to participants now, 10 under way, 3 of them phase 3. Coronary Artery Disease · Mexico.

Planned enrollment
15th of 26
1,400 · median 2,379
Started
2018
with 2 others
Phase 4
2 of 35
none open now
Registered
17th of 35
by date
Lead sponsor
5 of 35
Instituto Nacional de Cardiologia Ignacio Chavez

Among the 35 studies in Coronary Artery Disease with a site in Mexico, this one is the 15th largest by planned enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 4, and was the 17th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

8 of the 35 studies in Coronary Artery Disease with a site in Mexico are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Coronary Artery Disease with a site in Mexico, or all of them as a file.
02

Study summary

Femoral artery approach to perform coronary procedures is considered the standard technique for vascular access due to optimal catheter control, lower thromboembolic complications and immediate access due to the large diameter of the artery. Trans-radial approach has been shown to reduce major bleeding complications, vascular complications related to the site of puncture, including death from all causes, and to prevent post-procedure limb rest, greater comfort for patients, immediate ambulation, early discharge and reduction of costs. Previous studies have shown that intravenous, topical and intraarterial use of nitroglycerin produces vasodilation of the radial artery. Extravascular (subcutaneous) administration of nitroglycerin is extremely effective in restoring the radial pulse, and allows adequate cannulation.

Read the detailed description

Unlike femoral access, the trans-radial approach to coronary angiography requires a greater learning curve for the inexperienced interventionist, and demands a greater technical challenge than the femoral approach, which leads to a high incidence of failures and complications, mainly in the initial stages of their formation. Some explanations for procedural failure include inability for radial artery puncture, vessel tortuosity, and radial spasm. Radial spasm has been reported from 5 to 30% in experienced centers, with a decrease to 2.5% when associated with the administration of nitrate added to local anesthesia. Although radial spasm is infrequent and usually occurs once the artery is cannulated or during manipulation of the catheters, it can sometimes occur before cannulation due to multiple unsuccessful attempts to cannulate the artery, which can also produce pain in the patient.

The investigators will conduct an experimental, placebo-controlled, longitudinal, prospective, double-blind, parallel arm clinical trial. Patients will be randomized to receive 1:1 an intervention or placebo. Intervention group will receive a subcutaneous "cocktail" with 0.5 ml of 500 mcg of nitroglycerin + 1 ml of 2% simple lidocaine. Placebo group will receive a subcutaneous injection with 0.5 ml of 0.9% saline solution + 1 ml of 2% simple lidocaine.

The investigators hypothesize that the maneuver (subcutaneous infiltration of local anesthetic together with nitroglycerin) will facilitate radial access in terms of fewer punctures until the insertion of the arterial introducer, shorter access time, lower incidence of radial spasm, and lower crossover rate to femoral access, compared with placebo. In terms of safety, the investigators do not believe that the maneuver represents a risk to the patient in terms of incidence of hypotension or headache. In fact, the investigators believe that the maneuver will provide less pain at the site of puncture referred by the patient due to the less number of unsuccessful punctures.

For the calculation of the required sample, since the incidence of our primary end-point of a compound of crossover to femoral access and/or access site-related vascular complications has not been reported so far, the sample will be calculated with the rate of events obtained in our center at 6 months of recruiting patients. For this calculation, the proportional difference formula with an alpha value of 0,05 and a beta value of 0,20 will be used to have a statistical power of 80%. The investigators estimate that 1,500 patients will be required in a 11-month period.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Nitroglycerin
  • Vasodilator Agents
  • Subcutaneous Injection
  • Radial Artery
  • Coronary Angiography
  • Cardiac Catheterization
  • Coronary Angioplasty
  • Percutaneous Coronary Intervention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women older than 18 years, scheduled consecutively to perform a coronary procedure in the department of hemodynamics of the National Institute of Cardiology "Ignacio Chavez".
  • Patients may have any of the following indications for cardiac catheterization: Thoracic pain under study. Stable chronic coronary disease. Acute myocardial infarction with ST segment elevation, not perfused (without timely reperfusion therapy) with less than 4 weeks of evolution. Acute myocardial infarction with ST-segment elevation, successful thrombolytic therapy, which will undergo drug-invasive therapy. Acute myocardial infarction without ST segment elevation. Unstable angina. Any acute coronary syndrome, to intervene non-infarct-related artery. Disease of any heart valve. Myocarditis or pericarditis. Dilated cardiomyopathy. Patients in renal or cardiac transplantation protocol for any etiology. Congenital heart disease that requires knowing the coronary anatomy prior to surgical correction.
  • The planned procedure can be any of the following: For diagnostic purposes (coronary angiography only, left catheterization, left and right catheterization). For therapeutic purposes: percutaneous coronary intervention (PCI), with or without stent placement.
  • A priori access must be right or left radial artery.
  • Radial arterial pulse may be present or absent by palpation.
  • Modified Allen or Barbeau test should be positive (presence of collateral palmar flow).

Exclusion criteria

Exclusion Criteria:

  • Pregnant.
  • Not have for the present clinical trial, or do not fully understand the meaning of informed consent.
  • With acute myocardial infarction with ST segment elevation in the first 12 hours from the onset of symptoms.
  • With any acute coronary syndrome complicated with acute pulmonary edema, cardiogenic shock and / or malignant ventricular arrhythmias.
  • In which a cardiac catheterization is planned a priori to be performed via femoral, brachial or ulnar.
  • Patients in whom first attempt of arterial puncture is performed by 2nd year interventional cardiology fellow or by physician in charge.
  • Participating in another clinical trial.
  • Be allergic or have to nitroglycerin or other nitrates.
  • Any phosphodiesterase 5 inhibitor (sildenafil, tadalafil, avanafil, vardenafil) has been taken within 72 hours prior to the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
1,400 participants (estimated)

Study arms

  • Experimental
    Nitroglycerin

    The intervention group will receive a subcutaneous "cocktail" with 0,5 ml of 500 mcg of nitroglycerin + 1 ml of 2% simple lidocaine.

    Drug: Nitroglycerin 100 MCG/ML Injectable Solution

  • Placebo comparator
    Control

    The placebo group will receive a subcutaneous injection with 0,5 ml of 0,9% saline solution + 1 ml of 2% simple lidocaine.

    Drug: Saline Solution

Interventions

  • DrugNitroglycerin 100 MCG/ML Injectable Solution

    Drug page: Nitroglycerin

    Previously described.

  • DrugSaline Solution

    Previously described.

06

What researchers measure

Primary outcomes

  1. Compound of crossover to femoral access and/or access site-related vascular complications.

    Crossover to femoral access: number of cases in which the procedure could not be completed via radial artery and access via femoral artery was changed. Access site-related vascular complications: hematoma requiring intervention as an additional compression bandage, radial perforation / dissection, hemorrhage requiring transfusion, compartment syndrome, arteriovenous fistula, pseudoaneurysm, or any complication requiring surgical intervention.

    Time frame: Within 72 hours or at hospital discharge (whichever occurs first).

Secondary outcomes

  1. Number of attempts to cannulate the radial artery (punctures).

    Number of times the needle is inserted through the skin with the intention of puncturing the radial artery. This outcome measure will be assessed by interventional cardiology fellow who applies the maneuver and attempt to cannulate the artery.

    Time frame: Through study completion, an average of 1 year.

  2. Time until obtaining the radial access.

    Counted from the first attempt to puncture the radial artery, from the needle through the skin to the successful insertion of the introducer into the radial artery with adequate blood return.

    Time frame: Through study completion, an average of 1 year.

  3. Improvement in radial pulse strength.

    The interventional cardiologist fellow who will apply the maneuver, will assess the strength of the radial pulse before the administration of the maneuver and at least 1 minute after, and will record the change in pulse strength. Pulse Score: 0 - No palpable pulse. 1 - Weak pulse. 2 - Pulse of normal intensity. 3 - Very intense pulse.

    Time frame: Through study completion, an average of 1 year.

  4. Loss of radial artery flow (radial artery occlusion) at 30 days.

    The maximum longitudinal and transverse diameter of the radial artery and the maximum arterial flow velocity will be measured, with the transducer placed 1 cm proximal to the styloid process using ultrasound doppler with a vascular transducer.

    Time frame: At 30 days.

  5. Pain in the cannulated extremity.

    It will be evaluated with a visual-analogue subjective pain scale from 1 to 10 referred by the patient. Pain will be assessed at the time of introducing the radial introducer.

    Time frame: Through study completion, an average of 1 year.

  6. Radial spasm.

    It will be referred to as radial spasm if the patient reports pain or discomfort of any intensity at the cannulated end, at the time of manipulating, advancing and / or withdrawing any catheter through the arterial introducer. Angiographic confirmation of spasm may or may not be done. Additional intra-arterial vasodilators, or additional IV analgesics, may or may not be administered at the discretion of the operator.

    Time frame: During coronary procedure.

  7. Headache.

    Referred by the patient during any time of the procedure in the hemodynamic laboratory. It will be recorded on a subjective-to-analogue subjective pain scale from 1 to 10.

    Time frame: During coronary procedure.

  8. Hypotension.

    Systolic blood pressure lower than 90 mmHg in the following 10 minutes after the maneuver, not related to the manipulation of a coronary artery with any device.

    Time frame: In the following 10 minutes after administration of the maneuver.

07

Study locations

1 site
  • Instituto Nacional de Cardiologia Ignacio Chavez
    Mexico City, Tlalpan 04480, Mexico
08

References and documents

Individual participant data

Plan to share: Undecided — I will show the IPD during my research seminar wich is part of the program to being doctor in medical sciences to obtain a PhD degree.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Mar 2019, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2017
First posted
Oct 9, 2017
StartActual
Mar 30, 2018
Primary completionActual
Mar 30, 2019
CompletionEst.
Mar 31, 2026
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03304496
Lead sponsor
Instituto Nacional de Cardiologia Ignacio Chavez
Responsible party
Daniel Coutiño-Castelán (Principal Investigator, Instituto Nacional de Cardiologia Ignacio Chavez) — Principal investigator
First posted
Oct 9, 2017
Start date
Mar 30, 2018
Primary completion
Mar 30, 2019
Completion
Mar 31, 2026 (estimated)
Last update
Mar 18, 2026

Study contacts

Marco Antonio Peña Duque, MD
study director · Director of Department of Interventional Cardiology, National Institute of Cardiology, Mexico City, Mexico.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitroglycerin

Start the discussion